Skip to main content

ROIV Roivant Sciences Ltd.

Healthcare

35.89 -1.02 -2.76% Close 11/2
Since 2024-12-02 +195.8%
Open
36.95
High
37.29
Low
35.81
Prev close
36.91
Volume
5.7M
Amplitude
4.01%
P/B
6.3
Revenue YoY (TTM)
-67.6%
52W 19.30 42.50

Is Roivant Sciences Ltd. a buy? Fundamentals and valuation first

As of 2026-10-30

Momentum: Strong, Risk / liquidity: Good; Valuation: Pricey, Quality: Weak, Growth: Weak.

Valuation Pricey Free-cash-flow yield is Average; Price / book is Expensive.
TTM P/E -83.89 N/A
Price / book 6.3 86th percentile Expensive
Free-cash-flow yield (%) -3.05 36th percentile Average
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Weak ROE, TTM is Average; Operating margin, TTM is Lagging.
ROE, TTM (%) -6.29 33th percentile Average
Operating margin, TTM (%) -18,140.92 1th percentile Lagging
FCF margin, TTM (%) -10,806.61 2th percentile Lagging
Quality Factor Investing: A US Quality Value Backtest
Growth Weak Diluted EPS growth, TTM YoY is Average; Revenue growth, TTM YoY is Lagging.
Revenue growth, TTM YoY (%) -67.58 7th percentile Lagging
Diluted EPS growth, TTM YoY (%) -37.14 40th percentile Average
Momentum Strong All 2 indicators are Top.
60-day return (%) 5.1 81th percentile Top
240-day return (%) 81.91 94th percentile Top
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Good 20-day dollar volume is Top, but 60-day annualized volatility is Average.
20-day dollar volume 235,724,417 93th percentile Top
60-day annualized volatility (%) 51.8 57th percentile Average
Factor Investing Explained: 10 Classic Factors in US Stocks

Roivant Sciences Ltd. (ROIV) today

1 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From Roivant Sciences Ltd. to every stock like it

AI finds several complementary traits of Roivant Sciences Ltd. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Roivant Sciences Ltd.

Roivant Sciences Ltd. (ROIV) peers and tracking

Watchlist

This page refreshes daily after the close. Add Roivant Sciences Ltd. to your watchlist to track signal changes on your next visit.

Roivant Sciences Ltd. (ROIV) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Top-quintile 6-month momentum

Active · now 85.23%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
8 historical occurrences (since 2021-12-20)

Average forward return after Top-quintile 6-month momentum

20-day: Win 57.1%, Sample 7, Median +7.25%, Excess -0.33%, Beat mkt rate 57.1%

60-day: Win 83.3%, Sample 6, Median +15.7%, Excess +9.35%, Beat mkt rate 83.3%

120-day: Win 80%, Sample 5, Median +8.34%, Excess +14.71%, Beat mkt rate 60%

120 days after: historical avg +18.43%

20-day -0.69%
60-day +11.68%
120-day +18.43%
20-day
60-day
120-day
Win
57.1%
83.3%
80%
Sample
7
6
5
Median
+7.25%
+15.7%
+8.34%
Excess
-0.33%
+9.35%
+14.71%
Beat mkt rate
57.1%
83.3%
60%

Over 5 occurrences, 120-day forward avg gained 18.43%, beat the market by 14.71 pts; win rate 80%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

14 times historically; 60-day forward avg +3.64%, win rate 61.5%, beating the market by +2.17 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest

11 times historically; 60-day forward avg +13.93%, win rate 90.9%, beating the market by +10 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.